【摘要】 目的了解多发性骨髓瘤(MM)病人血清白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)的表达情况,并探讨沙利度胺联合化疗对MM病人血清IL-6、TNF-α的影响。方法用酶联免疫吸附试验(ELISA)方法测定30例正常人与79例MM病人血清IL-6、TNF-α的水平,并对MM病人不同临床分期,沙利度胺联合化疗前、后检测结果进行比较。结果MM病人血清IL-6、TNF-α的水平明显高于正常对照组,差异有显著性(t=8.117、11.525,P<0.001)。Ⅱ、Ⅲ期病人血清IL-6、TNF-α的表达水平明显高于Ⅰ期病人(F=4.233、10.273,q=3.012～6.294,P<0.05)。55例治疗有效的MM病人血清IL-6、TNF-α的水平治疗后较治疗前明显下降(t=3.153、4.361,P<0.01);治疗无效的22例MM病人治疗前、后血清IL-6、TNF-α水平无明显差异(t=0.850、0.913,P>0.05)。结论血清IL-6、TNF-α的水平在MM病人中呈高表达,且与其临床分期有关;沙利度胺联合化疗可显著降低MM病人血清IL-6、TNF-α的水平;检测血清IL-6、TNF-α的水平可作为判断MM疗效及病情的辅助指标。更多还原

【Abstract】 Objective To observe the serum levels of IL-6 and TNF-α in patients with multiple myeloma(MM),and explore the effects of thalidomide-combination chemotherapy on IL-6 and TNF-α.Methods The serum IL-6 and TNF-α in 79 MM patients and 30 normal controls were determined by ELISA,and the results of the patients in different stages as well as before and after therapy were compared.Results The concentrations of IL-6 and TNF-α in MM group were significantly higher than those in the control(t=8.117,11.525;P<0.001).The levels of IL-6 and TNF-α in stage Ⅲ and stage Ⅱpatients were higher than those of stageⅠ(F=4.233,10.273;q=3.012-6.294;P<0.05).Of 55 patients responding well to the therapy,levels of IL-6 and TNF-α declined significantly compared with before treatment(t=3.153,4.361;P<0.01),for 22 patients who showed poor response to the therapy,the serum parameters did not reveal significant difference from that of before medication(t=0.850,0.913;P>0.05).Conclusion The concentrations of IL-6 and TNF-α are high in MM patients,and associated with the clinical stages of the disease.The thalidomide-combined chemotherapy can significantly reduce the serum levels of IL-6 and TNF-α,a detection of this two items can be used as an auxiliary index in estimating the therapeutic efficacy and the condition of patients with MM.更多还原